High-CBD Cannatonic Phenotype — Clear-Headed Relief, Zero Intoxication
ACDC emerged as a selected phenotype of Cannatonic, a landmark hybrid created by Spanish seed bank Resin Seeds through a cross of MK Ultra (an indica-dominant OG Kush descendant) and G13 Haze (a sativa-heavy cultivar). While Cannatonic itself presents a range of CBD:THC ratios across seedlings — typically 1:1 to 5:1 — ACDC represents the rare high-CBD extreme, expressing ratios above 20:1 when correctly identified and propagated from seed.
Because the ACDC phenotype is not guaranteed from Cannatonic seeds, commercial cultivators rely on seedling chemotype screening (typically at 2–3 weeks of vegetative growth) to identify true ACDC plants. Once confirmed, mother plants are maintained and the strain propagated exclusively via cuttings to preserve genetic integrity. This clone-only model is standard across dispensary supply chains in California, Colorado, and Oregon.
The ACDC name gained widespread recognition through Project CBD and Steep Hill Laboratories in the early 2010s, when lab-verified CBD-rich cannabis was exceedingly rare. Its documented medical applications — spanning the Weed the People documentary and various paediatric epilepsy case studies — cemented its reputation as the benchmark high-CBD cannabis cultivar.
| Attribute | Detail |
|---|---|
| Parent Strain | Cannatonic (clone/phenotype selection) |
| Cannatonic Parents | MK Ultra × G13 Haze |
| Origin | California / Northern Spain (Resin Seeds) |
| Genetic Class | Sativa-dominant hybrid (60% sativa / 40% indica) |
| Propagation | Clone-only (phenotype verification required from seed) |
| CBD:THC Ratio | >20:1 (verified by Steep Hill Labs, SC Labs) |
| CBG Content | ~0.4–0.8% (minor cannabinoid) |
| CBDA Presence | Trace — minimal acidic precursor retained at harvest |
ACDC's terpene composition is dominated by myrcene, which contributes an earthy, musky base note and synergises with CBD to enhance muscle relaxation and sedation at higher doses. Caryophyllene, the only terpene that directly binds CB2 receptors, adds a peppery, spicy warmth and is strongly linked to the strain's anti-inflammatory properties. Alpha- and beta-pinene round out the profile with sharp coniferous freshness and have been studied for bronchodilatory and memory-retention effects.
The combined terpene load in verified ACDC samples typically sits at 1.5–2.5% total terpenes — notably high for a CBD-dominant cultivar, which often sacrifice aromatic complexity for cannabinoid yield. This robust terpene content is partly responsible for ACDC's enduring popularity over isolated CBD products and hemp-derived alternatives with flattened chemical profiles.
| Terpene | Avg % | Aroma | Primary Effect |
|---|---|---|---|
| Myrcene | 0.55–0.85% | Earthy, musky, herbal | Muscle relaxation, mild sedation, CBD synergy |
| β-Caryophyllene | 0.35–0.55% | Peppery, spicy, woody | Anti-inflammatory (CB2 agonist), anxiolytic |
| α-Pinene | 0.25–0.45% | Fresh pine, conifer | Bronchodilatory, memory retention, alertness |
| β-Pinene | 0.15–0.30% | Woody, green, fresh | Uplifting, anti-microbial, mood support |
| Ocimene | 0.05–0.15% | Sweet, floral, herbaceous | Anti-viral, mood elevation, minor contribution |
| Strain | CBD % | THC % | Type | Character |
|---|---|---|---|---|
| ACDC | 14–20% | <1% | CBD-Rich | Earthy-pine, clinically validated, clone-only |
| Cannatonic | 6–17% | 4–7% | Hybrid | Parent strain, mild psychoactivity possible |
| Charlotte's Web | 13–20% | <0.3% | CBD-Rich | Hemp-derived, floral, famous epilepsy use |
| Harlequin | 8–16% | 4–7% | Sativa | 5:2 CBD:THC, clearer head than pure CBD |
| Ringo's Gift | 13–20% | <1% | Hybrid | ACDC × Harle-Tsu cross, higher myrcene |
ACDC is one of the most consistently reported non-intoxicating cannabis strains in documented user surveys. Because THC content is below 1%, there is no euphoric effect, no impairment of cognitive function, and no risk of anxiety or paranoia — adverse effects sometimes associated with high-THC cultivars. Instead, users report a clear, focused calm that allows normal daily functioning while significantly reducing pain signals, muscle spasms, and anxiety symptoms.
In clinical and pre-clinical contexts, ACDC has been referenced in studies examining CBD's role in treatment-resistant epilepsy, neuroinflammation, and anxiety disorders. The whole-plant extract model — retaining CBD alongside myrcene, caryophyllene, and trace cannabinoids like CBG — is hypothesised to produce superior outcomes compared to CBD isolate, consistent with the entourage effect model proposed by Russo (2011) and Ben-Shabat (1998).
| Category | Effect / Condition | Mechanism | Evidence Level |
|---|---|---|---|
| Primary Effect | Deep relaxation | CBD + myrcene synergy on GABA pathways | High (user data + preclinical) |
| Primary Effect | Clear-headed focus | Pinene's acetylcholinesterase inhibition | Moderate (preclinical) |
| Primary Effect | Uplifted mood | Caryophyllene CB2 activation | Moderate (user survey) |
| Medical Use | Chronic pain / neuropathic pain | CBD modulates TRPV1 receptors | High (multiple RCTs) |
| Medical Use | Epilepsy / seizures | CBD reduces neuronal excitability | High (FDA-approved for related indication) |
| Medical Use | Multiple sclerosis spasticity | CBD + myrcene muscle relaxation | Moderate (observational) |
| Medical Use | Anxiety / PTSD | CBD's 5-HT1A partial agonism | High (clinical trials) |
| Medical Use | Systemic inflammation | Caryophyllene CB2 anti-inflammatory | Moderate (preclinical) |
ACDC is considered a moderate-difficulty cultivar, primarily because of the clone-only propagation requirement and the need for meticulous environmental control to maximise CBD expression without stressing the plant into producing excess THC. The sativa-dominant structure means plants stretch significantly during the first two weeks of flowering and benefit from low-stress training (LST) or a SCROG net to manage canopy height and improve light penetration.
CBD-rich strains like ACDC typically yield less densely than high-THC cultivars, producing airy, trichome-coated flowers rather than the compact, resin-saturated nuggets associated with OG or Kush genetics. Outdoor cultivation in warm, Mediterranean-style climates produces the best yields, with harvest timing in mid-October in the Northern Hemisphere. Post-harvest, a slow cure of 4–6 weeks at 58–62% RH is essential to preserve the delicate terpene profile and prevent CBD degradation.
| Parameter | Specification | Notes |
|---|---|---|
| Flower Time | 9–10 weeks (63–70 days) | Harvest when 10–15% amber trichomes visible |
| Yield (Indoor) | 350–450 g/m² | SCROG recommended; SOG suitable for clones |
| Yield (Outdoor) | 500–700 g/plant | Full sun, warm climate; harvest mid-October |
| Plant Height | 100–160 cm (indoor) | Sativa stretch — top at 30 cm or use LST |
| Temperature | 20–26°C (68–79°F) | Keep below 28°C to preserve CBD/terpenes |
| Humidity | Veg: 55–65% RH / Flower: 40–50% RH | Airy buds reduce mould risk; watch late flower |
| Training | LST, SCROG, light topping | Avoid heavy defoliation — sativa foliage thins naturally |
| Difficulty | Moderate | Clone availability and chemotype verification required |